Aytu BioPharma (NASDAQ:AYTU) Posts Earnings Results, Beats Estimates By $0.12 EPS

Aytu BioPharma (NASDAQ:AYTUGet Free Report) announced its quarterly earnings data on Wednesday. The company reported ($0.52) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.12, Zacks reports. The company had revenue of $17.99 million during the quarter. Aytu BioPharma had a negative net margin of 14.60% and a negative return on equity of 31.31%.

Aytu BioPharma Price Performance

Aytu BioPharma stock traded down $0.02 during trading hours on Friday, reaching $2.94. The stock had a trading volume of 21,134 shares, compared to its average volume of 17,146. Aytu BioPharma has a 52 week low of $1.38 and a 52 week high of $3.50. The company has a market cap of $16.38 million, a price-to-earnings ratio of -1.12 and a beta of -1.23. The business’s 50 day moving average price is $3.01 and its 200-day moving average price is $2.84.

About Aytu BioPharma

(Get Free Report)

Aytu Biopharma, Inc, a commercial-stage pharmaceutical company, focuses on commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates through two segments: Rx segment and Consumer Health segment. The Rx segment offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years and older, and Cotempla XR-ODT for patients from six to seventeen years old.

Featured Stories

Earnings History for Aytu BioPharma (NASDAQ:AYTU)

Receive News & Ratings for Aytu BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.